|
EP0368684B2
(en)
|
1988-11-11 |
2004-09-29 |
Medical Research Council |
Cloning immunoglobulin variable domain sequences.
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
|
FI941572A7
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
|
|
CA2372813A1
(en)
|
1992-02-06 |
1993-08-19 |
L.L. Houston |
Biosynthetic binding protein for cancer marker
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
MXPA06004035A
(es)
|
2003-10-16 |
2006-08-31 |
Micromet Ag |
Aglutinantes cd3 de-inmunizados multi-especificos.
|
|
CA2569509C
(en)
|
2004-06-03 |
2014-08-12 |
Novimmune S.A. |
Anti-cd3 antibodies and methods of use thereof
|
|
PL1874821T3
(pl)
*
|
2005-04-26 |
2013-09-30 |
Trion Pharma Gmbh |
Kombinacja przeciwciał i glikokortykoidów do leczenia raka
|
|
EP1940881B1
(en)
|
2005-10-11 |
2016-11-30 |
Amgen Research (Munich) GmbH |
Compositions comprising cross-species-specific antibodies and uses thereof
|
|
RU2769948C2
(ru)
|
2007-04-03 |
2022-04-11 |
Эмджен Рисерч (Мьюник) Гмбх |
CD3-Эпсилон-связывающий домен с межвидовой специфичностью
|
|
RS53008B2
(sr)
|
2007-04-03 |
2022-12-30 |
Amgen Res Munich Gmbh |
Interspecijski specifičan cd3-epsilon vezujući domen
|
|
SG10201405434VA
(en)
*
|
2009-09-18 |
2014-10-30 |
Amgen Res Munich Gmbh |
Dosage regimen for administering an epcamxcd3 bispecific antibody
|
|
EA026075B1
(ru)
*
|
2010-11-10 |
2017-02-28 |
Эмджен Рисерч (Мьюник) Гмбх |
Предотвращение неблагоприятных эффектов, вызванных cd3-специфическими связывающими доменами
|
|
KR102060389B1
(ko)
|
2011-05-21 |
2019-12-31 |
마크로제닉스, 인크. |
사람 및 비-사람 cd3에 결합할 수 있는 cd3-결합 분자
|
|
JP6509724B2
(ja)
|
2012-04-20 |
2019-05-08 |
アプティーボ リサーチ アンド デベロップメント エルエルシー |
Ｃｄ３結合ポリペプチド
|
|
EP2892924B1
(en)
|
2012-06-14 |
2020-11-25 |
Therapix Biosciences Ltd. |
Humanized antibodies to cluster of differentiation 3 (cd3)
|
|
WO2013188693A1
(en)
|
2012-06-15 |
2013-12-19 |
Imaginab, Inc. |
Antigen binding constructs to cd3
|
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
|
RU2015117393A
(ru)
*
|
2012-10-08 |
2016-12-10 |
Роше Гликарт Аг |
Лишенные fc антитела, содержащие два Fab-фрагмента, и способы их применения
|
|
KR102211837B1
(ko)
|
2013-01-14 |
2021-02-03 |
젠코어 인코포레이티드 |
신규한 이형이량체 단백질
|
|
LT2961771T
(lt)
|
2013-02-26 |
2020-03-10 |
Roche Glycart Ag |
Bispecifinės t ląstelę aktyvinančios antigeną surišančios molekulės, specifinės cd3 ir cea antigenams
|
|
JP6594855B2
(ja)
|
2013-03-15 |
2019-10-23 |
ゼンコア インコーポレイテッド |
ヘテロ二量体タンパク質
|
|
WO2015172800A1
(en)
|
2014-05-12 |
2015-11-19 |
Numab Ag |
Novel multispecific molecules and novel treatment methods based on such multispecific molecules
|
|
SG11201509361TA
(en)
|
2013-05-28 |
2015-12-30 |
Numab Ag |
Novel antibodies
|
|
ME03675B
(me)
|
2013-07-05 |
2020-10-20 |
Genmab As |
Humanizovana ili himerna anтi-cd3 antiтela
|
|
JP2016538275A
(ja)
|
2013-11-04 |
2016-12-08 |
グレンマーク ファーマシューティカルズ， エセ．アー． |
Ｔ細胞再標的化ヘテロ二量体免疫グロブリン（ｈｅｔｅｒｏ−ｄｉｍｅｒｉｃ ｉｍｍｕｎｏｇｌｏｂｕｌｉｎ）の製造
|
|
IL263466B2
(en)
|
2013-12-17 |
2023-10-01 |
Genentech Inc |
Anti-CD3 antibodies and methods of using them
|
|
CN106459201A
(zh)
|
2014-05-28 |
2017-02-22 |
豪夫迈·罗氏有限公司 |
结合人和食蟹猴CD3ε的抗体
|
|
CA2955947A1
(en)
|
2014-07-25 |
2016-01-28 |
Cytomx Therapeutics, Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
|
EP2982693A1
(en)
|
2014-08-07 |
2016-02-10 |
Affimed Therapeutics AG |
CD3 binding domain
|
|
CN120988137A
(zh)
|
2015-01-23 |
2025-11-21 |
赛诺菲 |
抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
|
|
TWI703159B
(zh)
|
2015-04-13 |
2020-09-01 |
美商輝瑞股份有限公司 |
Bcma特異性治療性抗體及其用途
|
|
EP3916018A1
(en)
|
2015-06-16 |
2021-12-01 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
|
US9914777B2
(en)
|
2015-07-10 |
2018-03-13 |
Merus N.V. |
Human CD3 binding antibody
|
|
IL256562B2
(en)
|
2015-07-15 |
2024-07-01 |
Genmab As |
Human CD3 antibodies or chimeras
|
|
WO2017053469A2
(en)
|
2015-09-21 |
2017-03-30 |
Aptevo Research And Development Llc |
Cd3 binding polypeptides
|
|
AU2016325630B2
(en)
|
2015-09-23 |
2022-11-17 |
Regeneron Pharmaceuticals, Inc. |
Optimized anti-CD3 bispecific antibodies and uses thereof
|
|
PE20180484A1
(es)
|
2015-10-02 |
2018-03-07 |
Hoffmann La Roche |
Moleculas biespecificas de union a antigeno activadoras de celulas t
|
|
KR20180097615A
(ko)
*
|
2016-01-08 |
2018-08-31 |
에프. 호프만-라 로슈 아게 |
Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
|
|
WO2017201493A1
(en)
|
2016-05-20 |
2017-11-23 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment cd3 binding proteins
|
|
KR20250175345A
(ko)
|
2016-06-21 |
2025-12-16 |
테네오바이오, 인코포레이티드 |
Cd3 결합 항체
|